Navigation Links
Initiation of Coverage Informational Review Issued by Scimitar Equity Research

BOSTON, Dec. 17 /PRNewswire/ -- Scimitar Equity Research, Inc. issues a review on Nventa Biopharmaceuticals Corporation (TSX: NVN) entitled: "A Very Promising Therapeutic and Vaccine Candidate for the Treatment of Diseases Caused by the Human Papillomavirus (HPV)." The analyst research is available on Scimitar's website:

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit

About HspE7, Nventa's Lead Product Candidate:

HspE7 is a novel therapeutic vaccine candidate for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Heat shock proteins (Hsps), also known as stress proteins, are naturally present in the human body and play important roles in the immune system, including transporting substances within cells and activating cells of the immune system.

Scimitar Equity Research, Inc. provides equity research of emerging healthcare companies for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about NVN.TO (TSX) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This sponsored analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.


Scimitar Equity Research, Inc.

Henry W. McCusker

Director of Research

phone: (617) 559.1080

fax: (617) 559.1083


SOURCE Scimitar Equity Research, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
4. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
5. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Post Your Comments:
(Date:11/24/2015)... , November 25, 2015 The ... to repeated failure of IVF cycles. After failure of ... dejected and had lost all hopes that she would be able to ... miracle child conceived after failure of over 15 IVF ... (UK) before they decided to take one last attempt with Gaudium ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk ... roadways has dropped below 10,000 for the first time since 2011. In 2014, there ... According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people ...
(Date:11/25/2015)... ... ... An unlikely combination of recycled plastic shopping bags in ... to have a more dignified and comfortable night’s sleep. , Residents of Friendship ... bags into sleeping mats for the homeless. The project, according to Jeannette ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... bunion treatment, is offering lower prices in an early celebration of the early ... the promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide variety ... Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, AZ ... the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient during ...
(Date:11/24/2015)... ... , ... DMG Productions announced that they will feature Aphria, Inc., in an ... Channel. Dates and show times TBA. , Aphria, Inc., is a publicly traded company ... and supplying medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). ...
Breaking Medicine News(10 mins):